Dual-specificity phosphatase 1-null mice exhibit spontaneous osteolytic disease and enhanced inflammatory osteolysis in experimental arthritis

Arthritis and Rheumatism

Volumn 64, Issue 7, 2012, Pages 2201-2210

  Vattakuzhi, Youridies ^a   Abraham, Sonya M ^b   Freidin, Andrew ^a   Clark, Andrew R ^a,c   Horwood, Nicole J ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTHRITIS; ARTICLE; BONE DESTRUCTION; CELL ACTIVATION; DISEASE SEVERITY; ENZYME DEFICIENCY; FINGER PHALANX; GENE DISRUPTION; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PENETRANCE; PRIORITY JOURNAL;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DUAL SPECIFICITY PHOSPHATASE 1; INFLAMMATION; JOINTS; MICE; MICE, KNOCKOUT; OSTEOCLASTS; OSTEOLYSIS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84863207135     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.34403     Document Type: Article

References (50)

1. Horwood N. Lymphocyte-derived cytokines in inflammatory arthritis. Autoimmunity 2008;41:230-8. (Pubitemid 351454994)
2. Hardy R, Cooper MS. Bone loss in inflammatory disorders. J Endocrinol 2009;201:309-20.
3. Zaidi M. Skeletal remodeling in health and disease. Nat Med 2007;13:791-801. (Pubitemid 47038187)
4. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998;139:4743-6. (Pubitemid 28487795)
5. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006;24:33-63.
6. Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun 1999;265:144-50.
7. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-9. (Pubitemid 129516268)
8. Quinn JM, Horwood NJ, Elliott J, Gillespie MT, Martin TJ. Fibroblastic stromal cells express receptor activator of NF-κB ligand and support osteoclast differentiation. J Bone Miner Res 2000;15:1459-66. (Pubitemid 30484515)
9. Walsh NC, Crotti TN, Goldring SR, Gravallese EM. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005;208:228-51. (Pubitemid 41746396)
10. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NF-B ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone 2002;30:340-6. (Pubitemid 34154863)
11. Huang H, Chang EJ, Ryu J, Lee ZH, Lee Y, Kim HH. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochem Biophys Res Commun 2006;351:99-105. (Pubitemid 44635412)
12. Mansky KC, Sankar U, Han J, Ostrowski MC. Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-κB ligand signaling. J Biol Chem 2002;277:11077-83. (Pubitemid 34952867)
13. Sharma SM, Bronisz A, Hu R, Patel K, Mansky KC, Sif S, et al. MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. J Biol Chem 2007;282:15921-9. (Pubitemid 47093311)
14. Kim JH, Kim K, Jin HM, Youn BU, Song I, Choi HS, et al. Upstream stimulatory factors regulate OSCAR gene expression in RANKL-mediated osteoclast differentiation. J Mol Biol 2008;383:502-11.
15. Li X, Udagawa N, Itoh K, Suda K, Murase Y, Nishihara T, et al. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 2002;143:3105-13. (Pubitemid 34809883)
16. Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL). J Biol Chem 2000;275:31155-61.
17. Huang H, Ryu J, Ha J, Chang EJ, Kim HJ, Kim HM, et al. Osteoclast differentiation requires TAK1 and MKK6 for NFATc1 induction and NF-κB transactivation by RANKL. Cell Death Differ 2006;13:1879-91. (Pubitemid 44542401)
18. So H, Rho J, Jeong D, Park R, Fisher DE, Ostrowski MC, et al. Microphthalmia transcription factor and PU.1 synergistically induce the leukocyte receptor osteoclast-associated receptor gene expression. J Biol Chem 2003;278:24209-16. (Pubitemid 36830257)
19. Matsumoto M, Kogawa M, Wada S, Takayanagi H, Tsujimoto M, Katayama S, et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004;279:45969-79. (Pubitemid 39491590)
20. Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, et al. A selective p38α mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis. J Pharmacol Exp Ther 2006;318:132-41.
21. Mbalaviele G, Anderson G, Jones A, De Ciechi P, Settle S, Mnich S, et al. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. J Pharmacol Exp Ther 2006;317:1044-53. (Pubitemid 43764107)
22. Yoshizawa T, Hammaker D, Boyle DL, Corr M, Flavell R, Davis R, et al. Role of MAPK kinase 6 in arthritis: distinct mechanism of action in inflammation and cytokine expression. J Immunol 2009;183:1360-7.
23. Bohm C, Hayer S, Kilian A, Zaiss MM, Finger S, Hess A, et al. The α-isoform of p38 MAPK specifically regulates arthritic bone loss. J Immunol 2009;183:5938-47.
24. Zwerina J, Hayer S, Redlich K, Bobacz K, Kollias G, Smolen JS, et al. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 2006;54:463-72.
25. Wei S, Siegal GP. p38 MAPK as a potential therapeutic target for inflammatory osteolysis. Adv Anat Pathol 2007;14:42-5.
26. Clark AR, Dean JL, Saklatvala J. The p38 MAPK pathway mediates both antiinflammatory and proinflammatory processes: comment on the article by Damjanov and the editorial by Genovese [letter]. Arthritis Rheum 2009;60:3513-4.
27. Owens DM, Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 2007;26:3203-13. (Pubitemid 46763015)
28. Abraham SM, Clark AR. Dual-specificity phosphatase 1: a critical regulator of innate immune responses. Biochem Soc Trans 2006;34:1018-23. (Pubitemid 46768980)
29. Abraham SM, Lawrence T, Kleiman A, Warden P, Medghalchi M, Tuckermann J, et al. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 2006;203:1883-9. (Pubitemid 44188463)
30. Chi H, Barry SP, Roth RJ, Wu JJ, Jones EA, Bennett AM, et al. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci U S A 2006;103:2274-9. (Pubitemid 43271660)
31. Hammer M, Mages J, Dietrich H, Servatius A, Howells N, Cato AC, et al. Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J Exp Med 2006;203:15-20. (Pubitemid 43139639)
32. Salojin KV, Owusu IB, Millerchip KA, Potter M, Platt KA, Oravecz T. Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol 2006;176:1899-907. (Pubitemid 43134335)
33. Zhao Q, Wang X, Nelin LD, Yao Y, Matta R, Manson ME, et al. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J Exp Med 2006;203:131-40. (Pubitemid 43139652)
34. Carlson J, Cui W, Zhang Q, Xu X, Mercan F, Bennett AM, et al. Role of MKP-1 in osteoclasts and bone homeostasis. Am J Pathol 2009;175:1564-73.
35. Sartori R, Li F, Kirkwood KL. MAP kinase phosphatase-1 protects against inflammatory bone loss. J Dent Res 2009;88:1125-30.
36. Yu H, Li Q, Herbert B, Zinna R, Martin K, Junior CR, et al. Anti-inflammatory effect of MAPK phosphatase-1 local gene transfer in inflammatory bone loss. Gene Ther 2011;18:344-53.
37. Inglis JJ, Simelyte E, McCann FE, Criado G, Williams RO. Protocol for the induction of arthritis in C57BL/6 mice. Nat Protoc 2008;3:612-8. (Pubitemid 351516757)
38. Hu M, Bassett JH, Danks L, Howell PG, Xu K, Spanoudakis E, et al. Activated invariant NKT cells regulate osteoclast development and function. J Immunol 2011;186:2910-7.
39. Dorfman K, Carrasco D, Gruda M, Ryan C, Lira SA, Bravo R. Disruption of the erp/mkp-1 gene does not affect mouse development: normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts. Oncogene 1996;13:925-31. (Pubitemid 26329078)
40. Joanny E, Ding Q, Gong L, Kong P, Saklatvala J, Clark AR. Anti-inflammatory effects of selective glucocorticoid receptor modulators are partially dependent on upregulation of dual specificity phosphatase 1. Br J Pharmacol 2012;165:1124-36.
41. Danks L, Workman S, Webster D, Horwood NJ. Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts. J Bone Miner Res 2011;26:182-92.
42. Wang X, Liu Y. Regulation of innate immune response by MAP kinase phosphatase-1. Cell Signal 2007;19:1372-82. (Pubitemid 46830880)
43. -/- mice in polymicrobial peritonitis models. Immunology 2010;131:395-404.
44. Frazier WJ, Wang X, Wancket LM, Li XA, Meng X, Nelin LD, et al. Increased inflammation, impaired bacterial clearance, and metabolic disruption after gram-negative sepsis in Mkp-1-deficient mice. J Immunol 2009;183:7411-9.
45. Wang X, Meng X, Kuhlman JR, Nelin LD, Nicol KK, English BK, et al. Knockout of Mkp-1 enhances the host inflammatory responses to gram-positive bacteria. J Immunol 2007;178:5312-20. (Pubitemid 46595317)
46. Li F, Zhang M, Hussain F, Triantaphyllopoulos K, Clark AR, Bhavsar PK, et al. Inhibition of p38 MAPK-dependent bronchial contraction after ozone by corticosteroids. Eur Respir J 2011;37:933-42.
47. Jin Y, Calvert TJ, Chen B, Chicoine LG, Joshi M, Bauer JA, et al. Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxia. Am J Physiol Heart Circ Physiol 2010;298:H1518-28.
48. Srivastava M, Solomon G, Strober B. Psoriatic onycho-pachydermo periostitis. Dermatol Online J 2007;13:20.
49. Fournie B, Viraben R, Durroux R, Lassoued S, Gay R, Fournie A. Psoriatic onycho-pachydermo-periostitis of the big toe: anatomoclinical study and physiopathogenic approach apropos of 4 cases. Rev Rhum Mal Osteoartic 1989;56:579-82. In French. (Pubitemid 19245577)
50. Bongartz T, Harle P, Friedrich S, Karrer S, Vogt T, Seitz A, et al. Successful treatment of psoriatic onycho-pachydermo periostitis (POPP) with adalimumab. Arthritis Rheum 2005;52:280-2. (Pubitemid 40129259)